William Blair Has Bullish Estimate for VRTX FY2025 Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Equities researchers at William Blair upped their FY2025 EPS estimates for Vertex Pharmaceuticals in a research report issued on Tuesday, May 6th. William Blair analyst M. Minter now anticipates that the pharmaceutical company will post earnings per share of $16.20 for the year, up from their previous forecast of $15.83. William Blair has a “Outperform” rating on the stock. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share. William Blair also issued estimates for Vertex Pharmaceuticals’ FY2026 earnings at $18.47 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. The business had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.85 billion. During the same period last year, the company earned $4.76 EPS. The business’s revenue was up 2.6% compared to the same quarter last year.

A number of other equities analysts have also commented on VRTX. Bank of America raised their target price on shares of Vertex Pharmaceuticals from $555.00 to $567.00 and gave the stock a “buy” rating in a research report on Monday, March 31st. BMO Capital Markets set a $545.00 target price on Vertex Pharmaceuticals in a research report on Friday, January 31st. Scotiabank dropped their price target on Vertex Pharmaceuticals from $450.00 to $442.00 and set a “sector perform” rating on the stock in a research report on Tuesday. Morgan Stanley lifted their price objective on Vertex Pharmaceuticals from $462.00 to $464.00 and gave the company an “equal weight” rating in a report on Tuesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $535.00 target price on shares of Vertex Pharmaceuticals in a report on Tuesday. Thirteen equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $515.04.

Vertex Pharmaceuticals Trading Down 1.0 %

NASDAQ VRTX opened at $425.30 on Friday. Vertex Pharmaceuticals has a 12 month low of $377.85 and a 12 month high of $519.88. The company’s 50-day moving average price is $488.74 and its 200-day moving average price is $465.90. The stock has a market cap of $109.34 billion, a PE ratio of -193.32, a PEG ratio of 2.11 and a beta of 0.51. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP David Altshuler sold 3,231 shares of the company’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $500.00, for a total value of $1,615,500.00. Following the sale, the executive vice president now directly owns 26,512 shares of the company’s stock, valued at approximately $13,256,000. This represents a 10.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Ourania Tatsis sold 310 shares of Vertex Pharmaceuticals stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $459.83, for a total value of $142,547.30. Following the transaction, the executive vice president now owns 64,021 shares of the company’s stock, valued at $29,438,776.43. The trade was a 0.48 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 4,315 shares of company stock worth $2,121,012. 0.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Blue Barn Wealth LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 1st quarter worth approximately $209,000. Altfest L J & Co. Inc. grew its position in Vertex Pharmaceuticals by 145.3% during the first quarter. Altfest L J & Co. Inc. now owns 1,646 shares of the pharmaceutical company’s stock valued at $798,000 after buying an additional 975 shares during the period. Foster Dykema Cabot & Partners LLC increased its holdings in Vertex Pharmaceuticals by 1.0% in the first quarter. Foster Dykema Cabot & Partners LLC now owns 61,455 shares of the pharmaceutical company’s stock valued at $29,795,000 after buying an additional 591 shares in the last quarter. Chicago Partners Investment Group LLC raised its position in shares of Vertex Pharmaceuticals by 17.5% in the first quarter. Chicago Partners Investment Group LLC now owns 948 shares of the pharmaceutical company’s stock worth $460,000 after acquiring an additional 141 shares during the period. Finally, Commonwealth Financial Services LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 1st quarter worth about $226,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.